Picard Medical Attends J.P. Morgan Healthcare Conference to Showcase Artificial Heart Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Globenewswire
- Industry Conference Participation: Picard Medical will attend the J.P. Morgan Healthcare Conference and related events on January 12 and 14, 2026, showcasing its innovations in cardiac care to enhance the company's visibility and influence in the healthcare sector.
- Technological Leadership: As the world's first manufacturer of a total artificial heart approved by both the FDA and Health Canada, Picard Medical's SynCardia system has performed over 2,100 implants across 27 countries, highlighting its market leadership in treating heart failure.
- Market Expansion Opportunities: By participating in LifeSci Advisors' Corporate Access Event, Picard Medical aims to engage in one-on-one meetings with potential investors and partners, further driving strategic collaborations and market expansion in the medtech field.
- Innovative Product Showcase: The SynCardia Total Artificial Heart is the only commercially available artificial heart in the U.S. and Canada, and this conference is expected to provide a crucial platform for future market promotion and product development.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
